TLE family member 5, transcriptional modulatorGenealiases: AES · AES-1 · AES-2 · ESP1 · GRG · GRG5
Q-omics provides the consensus-scored TLE5 profile across patient tissues and cancer cell-line models. TLE5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TLE5 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, TLE5 protein abundance shows 20,044 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight STAD, LUAD, and BRCA as cancer lineages where TLE5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLE5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLE5 survival associations across molecular data types. TLE5 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLE5 RNA expression–survival associations across cancer types. High TLE5 expression shows unfavorable associations in ACC and LGG, but favorable associations in STAD, UCEC, UVM and CESC. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for TLE5 RNA expression.
This table summarizes TLE5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TLE5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLE5 shows lower tumor expression in LUAD, BLCA, UCEC and LUSC and higher tumor expression in LIHC and CHOL. The LUAD box plot shows higher TLE5 RNA expression in normal versus tumor tissue (log2 FC = −0.631, t-test p < 0.001).
This table shows molecular features associated with TLE5 in patient tissues and cancer cell lines. In patient samples, TLE5 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TLE5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
